ONT-093 (Ontogen).

Abstract

Ontogen is developing ONT-093 (formerly OC-144-093), a P-glycoprotein pump inhibitor, for the potential reversal of multidrug resistance in patients undergoing cancer chemotherapy. The compound is also being evaluated for its potential enhancement of the oral bioavailability of drugs that are P-glycoprotein substrates requiring either high dosage forms or intravenous administration, and for the potential improvement of central nervous system penetration of P-glycoprotein substrate drugs.

• Authors: Prakash Mistry, Adrian Folkes
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 11 Pg. 1666-71 (Nov 2002) ISSN: 1472-4472 [Print] England
• PMID: 12476971 (Publication Type: Journal Article, Review)

Chemical References

• Imidazoles
• OC 144-093

Topics

• Animals
• Clinical Trials as Topic (statistics & numerical data)
• Drug Resistance, Multiple (physiology)
• Humans
• Imidazoles (chemistry, pharmacology, therapeutic use)
• Neoplasms (drug therapy, metabolism)
• Technology, Pharmaceutical (legislation & jurisprudence, methods)